Search research articles
Contact Us
Filters
Showing results (111-120 of 129) with videos related to
Page
of 13
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 1, 1984
Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial
P Carde, J M Burgers, M van Glabbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1988
Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors
P Carde, J M Burgers, M Henry-Amar, et al.
Blood
|
January 1, 1989
Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987
M Tubiana, M Henry-Amar, P Carde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1997
Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group
J H Meerwaldt, P Carde, R Somers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group
A Hagenbeek, P Carde, J H Meerwaldt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 1991
Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group
P Carde, J H Meerwaldt, M van Glabbeke, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 23, 2001
A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment
T Girinsky, D Guillot-Vals, S Koscielny, et al.
Journal of the National Cancer Institute
|
January 4, 2001
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study
H C Kluin-Nelemans, V Zagonel, A Anastasopoulou, et al.
Cancer Genetics and Cytogenetics
|
May 14, 2003
Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model
R M'kacher, F Farace, A Bennaceur-Griscelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1997
Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie
J Raemaekers, M Burgers, M Henry-Amar, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 129) with videos related to
Sort By:
Page
of 13
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 1, 1984
Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial
P Carde, J M Burgers, M van Glabbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 1988
Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors
P Carde, J M Burgers, M Henry-Amar, et al.
Blood
|
January 1, 1989
Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987
M Tubiana, M Henry-Amar, P Carde, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1997
Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group
J H Meerwaldt, P Carde, R Somers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group
A Hagenbeek, P Carde, J H Meerwaldt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 1991
Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group
P Carde, J H Meerwaldt, M van Glabbeke, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 23, 2001
A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment
T Girinsky, D Guillot-Vals, S Koscielny, et al.
Journal of the National Cancer Institute
|
January 4, 2001
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study
H C Kluin-Nelemans, V Zagonel, A Anastasopoulou, et al.
Cancer Genetics and Cytogenetics
|
May 14, 2003
Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model
R M'kacher, F Farace, A Bennaceur-Griscelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1997
Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie
J Raemaekers, M Burgers, M Henry-Amar, et al.
Page
of 13